Quick Enquiry
<

Ajanta Pharma Limited Investment Call


Posted on 2018-12-07 in WEALTH NOTE RESEARCH

 

AJANTA PHARMA                                                     CMP - 1155 

 





Image result for ajanta pharma limited








 




 




RATIOS




COMPANY VALUE




 




 




   SALES GROWTH 10 YEAR




21 %




   PROFIT GROWTH 10 YEAR




35 %




   AVERAGE RETURN ON EQUITY 5 YEAR




36 %




   AVERAGE RETURN ON ASSETS 5 YEAR




46 %




   OPERATING PROFIT MARGIN LAST YEAR




31 %




   NET PROFIT MARGIN LAST YEAR




22 %







DEBT TO EQUITY




0 %







INTEREST COVERAGE RATIO




1160







PROMOTER SHAREHOLDING




70.50 %







MARKET CAPITALISATION




10250 CRORES




 




 




 




 




 




 




VALUATION




RATIO




 







PRICE TO EARNING




21.56




 







INDUSTRY PE




30




 




   PRICE TO BOOK VALUE




5

 

 

 


Ajanta Pharma Limited is an multinational company based in India engaged in development, manufacturing, and marketing of pharmaceutical formulations. It has a presence in India, the United States, and about 30 other countries in Africa, Asia, Middle East, and CIS. It was established in, and ophthalmology.

It employ over 4,800 people worldwide and its products are sold in over 40 countries. Ajanta operates with 5 state-of-the art manufacturing facilities that produce high quality pharmaceutical products. It focus on commercializing unique generic products and pioneering synergistic combination products in the therapeutic areas of anti-malarial, Cardiovascular, dermatology, male erectile dysfunction, musculoskeletal In India, it has significant presence in the fast growing specialty therapeutic segments of Cardiovascular, dermatology, ophthalmology and musculoskeletal

 

Ajanta has extensive presence in many countries in Asia, Africa and Latin America with customized product portfolio to suit the needs of each country. Having successfully gone through USFDA inspection, it has started commercial operations in the US market in the first quarter of 2013. With a portfolio of 23 ANDAs (As on March 31, 2014) which have been filed with the US FDA, it look forward to the US market to be its key growth driver in coming years.

 

The company is having an advanced Research & Development Centre for finished formulations and Active Pharmaceutical Ingredient (API) synthesis of different dosage forms. ˜Adventa,. It has acquired strong capabilities for developing generic formulations and process chemistry over the years. Committed to patient care since inception, the focus on specialty segments in India and simultaneous opening of new international markets has been accelerating its growth over the years

 

 Disclaimer : This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Wealth Note Investments has not independently verified all the information contained within this document. This should not be considered to be taken as an offer to sell or a solicitation to buy any security. Neither Wealth Note Investments nor its owners, or employees shall be liable for any loss or damage that may arise from or in connection with the use of this information. Please consult you financial advisor before taking any new trading or investment decision.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 







Call Now